^{NOT FOR RELEASE OT DISTRIBUTION IN THE USA, CANADA, AUSTRALIA OR JAPAN.}
 

Preliminary sales: SHOP APOTHEKE EUROPE achieves an excellent start into the financial year 2018 with a 105 % revenue increase in Q1.

• Group revenues more than doubled to EUR 131 million in first quarter.
• Growth rate 105% after 58% in the same quarter of the previous year.
• Guidance for the financial year 2018 confirmed.

Venlo, 25 April 2018. SHOP APOTHEKE EUROPE N.V., the leading online pharmacy in Continental Europe, has achieved a dynamic start into the 2018 financial year (01.01.-31.12.), thus further expanding its market position in Germany and Continental Europe. Supported by the integration of Europa Apotheek which was acquired in November 2017, SHOP APOTHEKE EUROPE again increased its growth rate and boosted group revenues by 105% to EUR 131 m. Management Board reaffirms its guidance for revenue growth to EUR 530 m to 560 m (+87% to +97%) and a positive EBITDA* of EUR 0 to 2 m at Group level.
 

The integration and consolidation of Europa Apotheek led to a significant acceleration in growth in the "Germany" segment. In Continental Europe's largest online pharmacy market and SHOP APOTHEKE EUROPE's core market, revenues in the first quarter rose by 118% to EUR 103.5 m (EUR 47.5 m in the previous year).

SHOP APOTHEKE EUROPE also recorded a dynamic growth in the international markets, including Austria, France, Belgium, the Netherlands, Spain and Italy. Business volume in the "International" segment was up by EUR 11.1 m in absolute terms from EUR 16.0 m to EUR 27.1 m. This corresponds to a growth of more than 69%.

Based on the strong growth in the first quarter, Management Board reaffirms its guidance for the financial year 2018: The planned increase in group revenues of 87% to 97% to EUR 530 m to 560 m will particularly be driven by the growing international business and the consolidation of Europa Apotheek. Due to further gains in efficiency and economies of scale, the company also plans to achieve a positive EBITDA* of EUR 0 to 2 m at Group level.

Potential acquisitions are not included in the forecast for the full year. SHOP APOTHEKE EUROPE intends to maintain its active role in the ongoing market consolidation. In order to be able to act swiftly and to take advantage of upcoming target opportunities in a flexible way, the company successfully placed EUR 75m convertible bonds with institutional investors on April 12. Net proceeds will primarily be used to finance OTC acquisitions in the German market to further accelerate the Group's growth in its most developed core market.

Dr. Ulrich Wandel, CFO of SHOP APOTHEKE EUROPE N.V., adds: "The successful issuance of convertible bonds by SHOP APOTHEKE EUROPE N.V. confirms the high confidence of the capital markets in our European growth story".

_{* before one-off costs}

_{All published figures are preliminary and unaudited. SHOP APOTHEKE EUROPE will publish the complete interim statement for the first quarter of 2018 as scheduled on 15 May 2018.}

ABOUT SHOP APOTHEKE EUROPE.

SHOP APOTHEKE EUROPE is the leading and fastest growing online pharmacy in Continental Europe. SHOP APOTHEKE EUROPE already operates online pharmacies in Germany, Austria, France, Belgium, Italy, Spain and the Netherlands. In Germany, the TÜV-certified shop-apotheke.com is the market leading. SHOP APOTHEKE EUROPE delivers a broad range of more than 100,000 original products to about 2.8 million active customers quickly and at attractive prices. In addition, SHOP APOTHEKE EUROPE provides comprehensive and consistent pharmaceutical services.SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 13 October 2016.

MEDIA CONTACTS.

Trade and public media:
Sven Schirmer
Mobile: +49 152 28 50 63 61
Email: presse@shop-apotheke.com

Financial media:
Thomas Schnorrenberg
Mobile: +49 151 46 53 13 17
Email: presse@shop-apotheke.com

Investor Relations:
Dr. Ulrich Wandel
Telephone: +31 77 850 6117
Email: ulrich.wandel@shop-apotheke.com

DISCLAIMER.

This publication is an advertisement.
This communication constitutes neither an offer to sell nor a solicitation to buy securities of Shop Apotheke Europe N.V. in any jurisdiction. This is not a securities prospectus. No public offering of any securities of Shop Apotheke Europe N.V. is being made.

Statements contained herein may constitute "forward-looking statements." Forward-looking statements are generally identifiable by the use of the words "may", "will", "should", "plan", "expect", "anticipate", "estimate," "believe", "intend", "project", "goal" or "target" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are based on current expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Group's or its industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. You should not place undue reliance on forward-looking statements and the Group does not undertake publicly to update or revise any forward-looking statement that may be made herein, whether as a result of new information, future events or otherwise.